跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 359 条关于
“Cullinan Pearl”
全部
359
临床试验
273
药物
13
机构
12
资讯
61
4年前
Cullinan Oncology and Taiho Pharmaceutical Forge $275M Strategic Collaboration for EGFR Inhibitor CLN-081/TAS6417
去年
PEARL Study: Durvalumab Monotherapy Shows Promise in NSCLC Patients with High PD-L1 Expression
4个月前
Analysts Maintain Strong Buy Consensus on Cullinan Management (CGEM) with Significant Upside Potential
去年
Pearl Achieves Historic FDA Clearance for First AI Platform Supporting Both 2D and 3D Dental Imaging Analysis
去年
Cullinan Therapeutics Licenses BCMA-Targeted Bispecific T Cell Engager for Autoimmune Disease Development
上个月
Cullinan Therapeutics Reports $53.7 Million Q2 Loss, Missing Analyst Expectations
去年
Cullinan Therapeutics Advances Novel CD19 T Cell Engager for Autoimmune Disease Treatment
去年
Cullinan Management's Zipalertinib Shows Promise in NSCLC, Bolstering Stock Rating
2年前
Cullinan Therapeutics Advances CLN-978 for SLE Treatment with Phase 1 Trial Approval
去年
Cullinan Therapeutics Advances Novel CD19 T Cell Engager to Phase 1 Trial for Rheumatoid Arthritis in Europe
第 1 页,共 7 页
上一页
下一页